GBA Presents: RADIO SAVANT-!

[vanzandt]

ADDING SNAP at $27.50!

You don't wanna look.
SNAP is crashing.
And I kid you not, I thought the bottom was in and I actually thought about buying some at $22 on your summer rally theory.

SNAP>>>> $17.20

Looks like they guided revenue below what they said in April.
They did that once before too. Yikes.
Man those class-action attorneys are already on their way to the courthouse's in the 3 time-zones they're still open in.

 

[vanzandt]

Damn Stoney.
It's taking the whole market down.
Google, FB, RBLX, even TSLA fell on the news.
Your Q's are down $4

So much for the Summer-Rally Stoney.
SNAP just announced via an 8-K with the SEC what The Savant said last week.
Things are ugly and getting worse.

BTW, Zoom is $95 now. I gave ya the short call at $107 Stoney. You missed $12 on the way down too.

 

[vanzandt]

SNAP 8K:

Item 7.01 Regulation FD Disclosure.

Since we issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and faster than anticipated.

As a result, we believe it is likely that we will report revenue and adjusted EBITDA below the low end of our Q2 2022 guidance range. We remain excited about the long-term opportunity to grow our business. Our community continues to grow, and we continue to see strong engagement across Snapchat, and continue to see significant opportunities to grow our average revenue per user over the long term.

 

[stonedinvestor]

Van I violated one of the core principles of stonedinvesting.
It's like walking in on your Mother naked.
I'm screwed.

When I teach these seminars I say YOU CAN NEVER LOOK! Don't watch the ticker... Don't anticipate an up or down day...

Don't read your statements. If you want to achieve SAVANT level you have to know nothing. And then of course everything. Fear can play no role in the process.

SEED might be the last stock the old stoney bought. The free wheeling maniac we all love. He may be gone. Dead and buried in a mountain of reality.

 

[vanzandt]

Van I violated one of the core principles of stonedinvesting.
It's like walking in on your Mother naked.
I'm screwed.

When I teach these seminars I say YOU CAN NEVER LOOK! Don't watch the ticker... Don't anticipate an up or down day...

Don't read your statements. If you want to achieve SAVANT level you have to know nothing. And then of course everything. Fear can play no role in the process.

SEED might be the last stock the old stoney bought. The free wheeling maniac we all love. He may be gone. Dead and buried in a mountain of reality.

Just listen to me and you'll be fine.
Zoom is $92 and falling fast.
My $107 call is worth $15 now.

guidance sux
That $107, its a squeeze.
It's gonna drop
Tomorrow at least

Granny's shorts Stoney $107
Get it!

 

[stonedinvestor]

Mersana Therapeutics director Hack buys 216K shares of stock 17:56 MRSN Mersana Therapeutics director Andrew Hack purchased 215,599 shares of company stock at at $3.46 per share per share between May 19 and May 23, for a total transaction amount of $746,447.

This is our active gummy--- BUY

 

[stonedinvestor]

Red Cat completes production of four-drone, multi-vehicle system 07:06 RCAT Red Cat Holdings…

Best Buy cuts FY23 EPS view $8.40-$9.00 from $8.85-$9.15, consensus $8.90 07:06 BBY Cuts FY23 revenue view to…

California Resources, Denbury may be takeout targets, says Citi 07:01 CRC, DEN Citi analyst Scott Gruber says California Resources (CRC) and Denbury (DEN) shares should outperform in a recession given the companies' "clean" balance sheets, while climate technology "could see renewed interest if interest rates stop going up." The analyst also believes both California Resources and Denbury could be acquisition targets. The business models overall appear to be in the "wheelhouse of the integrated oil companies already in the business or could view DEN/CRC as an entry point," Gruber tells investors in a research note. He keeps a Buy rating on both stocks.

Rapt Therapeutics assumed with an Overweight at Cantor Fitzgerald 06:52 RAPT Cantor Fitzgerald analyst Prakhar Agrawal assumed coverage of Rapt Therapeutics with an Overweight rating with a price target of $44, down from $58. RPT193, Rapt's lead inflammation drug, could be a $3B+ drug just in the Atopic Dermatitis indication, Agrawal tells investors in a research note, with the analyst's conviction driven by the firm's comprehensive review of phase 1 efficacy, which was remarkably strong in the more severe sub-group and looks very competitive to Dupixent and JAKs. Based on the firm's estimates, the current stock price seems to be pricing in only ~$700M-$800M in peak annual revenue across all assets, Agrawal contends.

 

[vanzandt]

Red Cat completes production of four-drone, multi-vehicle system 07:06 RCAT Red Cat Holdings…

Best Buy cuts FY23 EPS view $8.40-$9.00 from $8.85-$9.15, consensus $8.90 07:06 BBY Cuts FY23 revenue view to…

California Resources, Denbury may be takeout targets, says Citi 07:01 CRC, DEN Citi analyst Scott Gruber says California Resources (CRC) and Denbury (DEN) shares should outperform in a recession given the companies' "clean" balance sheets, while climate technology "could see renewed interest if interest rates stop going up." The analyst also believes both California Resources and Denbury could be acquisition targets. The business models overall appear to be in the "wheelhouse of the integrated oil companies already in the business or could view DEN/CRC as an entry point," Gruber tells investors in a research note. He keeps a Buy rating on both stocks.

Rapt Therapeutics assumed with an Overweight at Cantor Fitzgerald 06:52 RAPT Cantor Fitzgerald analyst Prakhar Agrawal assumed coverage of Rapt Therapeutics with an Overweight rating with a price target of $44, down from $58. RPT193, Rapt's lead inflammation drug, could be a $3B+ drug just in the Atopic Dermatitis indication, Agrawal tells investors in a research note, with the analyst's conviction driven by the firm's comprehensive review of phase 1 efficacy, which was remarkably strong in the more severe sub-group and looks very competitive to Dupixent and JAKs. Based on the firm's estimates, the current stock price seems to be pricing in only ~$700M-$800M in peak annual revenue across all assets, Agrawal contends.

Did we switch back?

 

[stonedinvestor]

Canadian Solar reports Q1 EPS 14c, consensus (13c) 06:05 CSIQ Reports Q1

Albemarle price target raised to $320 from $290 at Deutsche Bank 06:49 ALB Deutsche Bank analyst…

Albemarle price target raised to $320 from $285 at Wells Fargo » 06:46 ALB Wells Fargo anal

Albemarle price target raised to $314 from $300 at RBC Capital 06:23 ALB RBC Capital analyst Arun Viswanathan raised the firm's price target on Albemarle to $314 from $300 and keeps an Outperform rating on the shares after the company raised its FY22 guidance due to better than expected progress in shifting Lithium customers towards variable priced contracts. Viswanathan adds that he has lowered his forward EBITDA multiple estimate to 20-times from 22-times due to "peak pricing", though his FY23 outlook of $2B is below consensus $2.1B to "build in a cushion" as pricing moderates.

AST SpaceMobile price target lowered to $31 from $32 at Deutsche Bank » 06:48 ASTS Deutsche Bank analyst…

Citi Trends reports Q1 adjusted EPS 42c, consensus 34c » 06:47 CTRN Reports Q1 revenue $208M,…

STOCK OF THE DAY- HILLEVAX

HilleVax initiated with a Buy at Guggenheim 06:22 HLVX Guggenheim analyst Seamus Fernandez initiated coverage of HilleVax with a Buy rating and $40 price target.

->GUMMY- HLVX $9.50

 

[stonedinvestor]

Snowflake upgraded to Buy from Neutral at Rosenblatt 05:15 SNOW Rosenblatt analyst Blair Abernethy upgraded Snowflake to Buy from Neutral with a $255 price target.

2ND STOCK OF THE DAY SNOWFLAKE-

Snowflake upgraded to Buy into Q1 results at Rosenblatt 05:21 SNOW Rosenblatt analyst Blair Abernethy upgraded Snowflake to Buy from Neutral with a price target of $255, down from $325, ahead of the company's fiscal Q1 results on May 25. The analyst expects Snowflake to meet or marginally exceed his Q1 product revenue growth estimate of 81% year-over-year given ongoing enterprise digital transformation momentum. Due to the recent significant decline in the stock price, the revised target price reflects an 84% return from current levels, Abernethy tells investors in a research note.